Two of these hotspots presented cancer stage specificity: HRAS G13 mutations were enriched in TMD in late-stage cancers, while KRAS G12 mutations were depleted in early-stage tumors (Supplementary Figures 9B, 10B). This evidence concerns the gene HRAS and cancer.